Fig. 2From: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review studyProgression-Free Survival1. Abbreviations: 2 L: second-line; 3 L: third-line. Notes: [1] Disease progression was defined as a record of discontinuation due to progressive disease, progressive disease as a patient’s best response to a treatment regimen, or death and was measured from the index date onward. Patients were censored at the earliest between initiation of a new line of therapy or end of follow-up, whichever occurred firBack to article page